

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/36019> holds various files of this Leiden University dissertation.

Author: Malan, Daniel Francois

Title: Pinning down loosened prostheses : imaging and planning of percutaneous hip refixation

Issue Date: 2015-10-29

3

Percutaneous bone cement refixation of aseptically loose hip prostheses: the effect of interface tissue removal on injected cement volumes

Daniel F. Malan, Edward R. Valstar, Rob G.H.H. Nelissen

Adapted from:
Skeletal Radiology,
Volume 43, Issue 11, pp 1537–1542, November 2014.
doi: 10.1007/s00256-014-1924-4

Abstract

Objective

To quantify whether injected cement volumes differed between two groups of patients who underwent experimental minimally invasive percutaneous cement injection procedures to stabilize aseptically loose hip prostheses. One patient group was preoperatively treated using gene-directed enzyme prodrug therapy to remove fibrous interface tissue, while the other group received no preoperative treatment. It was hypothesized that cement penetration may have been inhibited by the presence of fibrous interface tissue in periprosthetic lesions.

Materials and Methods

We analyzed 17 patients (14 female, 3 male, ages 72-91, ASA categories 2-4) who were treated at our institution. Osteolytic lesions and injected cement were manually delineated using 3D CT image segmentation, and the deposition of injected cement was quantified.

Results

Patients who underwent preoperative gene-directed enzyme therapy to remove fibrous tissue exhibited larger injected cement volumes than those who did not. The observed median increase in injected cement volume was 6.8 ml. Higher cement leakage volumes were also observed for this group.

Conclusion

We conclude that prior removal of periprosthetic fibrous interface tissue may enable better cement flow and penetration. This might lead to better refixation of aseptically loosened prostheses.

3.1 Introduction

Standard treatment of symptomatic aseptic loosening of a hip prosthesis comprises revision of the loose components, with concomitant removal of the fibrous interface tissue that formed in the periprosthetic osteolytic bone lesions [Bauer and Schils, 1999, Sundfeldt et al., 2006]. Worldwide, the rate of hip prosthesis revision at 10 year follow-up is estimated at 12% [Labek et al., 2011]. Revision rates are predicted to increase in the coming decades [Kurtz et al., 2007].

Revision surgery has higher perioperative mortality and morbidity rates in elderly and high-risk groups, with some authors reporting up to 51% postoperative complications in these patients [Strehle et al., 2000]. In the subset of patients with significant comorbidity the risks of revision surgery might outweigh the benefits. Percutaneously injecting bone cement into the periprosthetic osteolytic lesions was demonstrated as an experimental alternative treatment for these symptomatic patients [de Poorter et al., 2005, de Poorter et al., 2008a, Raaijmakers and Mulier, 2010]. During this procedure one or more hollow vertebroplasty needles are inserted under spinal anaesthesia, and vertebroplasty cement is injected into the periprosthetic space to stabilize and fixate the loosened prosthesis [Raaijmakers and Mulier, 2010, de Poorter et al., 2008b].

The incompressible periprosthetic fibrous tissue is not removed during percutaneous cement injection and might impede sufficient cement flow. De Poorter et al. investigated pre-operatively removing interface tissue by using a gene-directed enzyme prodrug therapy (GDEPT) approach [de Poorter et al., 2005, de Poorter et al., 2008a]. However, it remained unclear whether cement volumes following GDEPT differed from those cases where interface tissue were left intact.

The aim of this study was to quantify whether injected cement volumes differed between patients who underwent percutaneous cement injection only, compared to those who also underwent pre-operative gene-directed enzyme prodrug therapy to remove fibrous interface tissue.

3.2 Materials and Methods

Our candidate population consisted of twenty two patients at our hospital who consecutively underwent hip stem refixation by means of percutaneous bone cement injection. CT image data were collected retrospectively. Before 2006, CT imaging was not standard after cement injection at our hospital

and we consequently had to exclude patients for whom no post-operative CT images were available. The study was performed under approval of the Medical Ethics Committee (CME) of our institution.

Our study population comprised two groups that were treated consecutively, not blinded, and over the course of several years. The twelve patients in the “GDEPT group” had interface tissue treated with gene directed enzyme therapy prior to cement injection as described by [de Poorter et al., 2008a, de Poorter et al., 2008b]. Each had a single hip treated between 2004 and 2006. Of these patients five were excluded due to post-procedure CT image volumes not being available, yielding a total of 7 GDEPT hips for our analysis. The “cement-only” patients received no treatment before cement injection and were treated between 2005 and 2011. One patient was excluded due to no post-procedure CT being available. Of the remaining nine patients, one patient was treated bilaterally. For this patient we included both hips separately in the analyses, yielding a total of 10 cement-only hips.

Of the 17 hips investigated in this study 14 were from female patients, and 3 from male patients. The median age at operation of the patients was 82 years (range 72-91). All patients presented with invalidating hip pain, and all were deemed unfit for traditional revision surgery. The American Society of Anesthesiologists (ASA) classifications [Owens et al., 1978] of the patients ranged from ASA-2 to ASA-4. There was no difference in the age distribution between the cement-only and GDEPT groups.

Percutaneous bone cement injection was performed in all patients by the method described by [de Poorter et al., 2008a, de Poorter, 2010, de Poorter et al., 2008b] (Figs. 3.1–3.2). All procedures were performed under guidance by the same orthopaedic surgeon and intervention radiologist. Patients underwent CT guided percutaneous injection of polymethyl-methacrylate (PMMA) cement (Osteopal, Biomet; Disc-O-Tech, Disc-O-Tech Medical technologies, Herzeliya, Israel; Vertaplex, Stryker Orthopaedics, Michigan, USA) via vertebroplasty needles of 3.2 x 100 mm (Biomet, Dordrecht, The Netherlands). Cement injection was performed under spinal anaesthesia and guided fluoroscopically. Cement injection was halted either when the target lesion was filled to the extent that additional cement flow leaked beyond the intended region (i.e. extra osseously), or when cement flow ceased due to being high resistance at the injection cannula (Fig. 3.4). A post-operative CT scan of the hip was made on the same day as the minimally invasive procedure.



Figure 3.1 – Cement being percutaneously injected into the periprosthetic space via vertebroplasty needles

The extent of the pre-operative osteolytic zones and the injected cement volumes were measured in three dimensions using the acquired CT image volumes. The image volumes were created on a helical CT scanner (Toshiba Aquilion, Toshiba Medical Systems, Japan) with slice thicknesses ranging from 0.4 mm to 1.0 mm, and in-plane resolutions between 0.39 mm and 0.74 mm. Osteolytic lesions and cement volumes were manually segmented by an expert user in a slice-by-slice fashion using the Medical Imaging Interaction Toolkit (MITK 0.12.2), an interactive medical image segmentation software tool [Maleike et al., 2009] (Fig. 3.5).

In a previously published cadaveric study examining periprosthetic femoral lesions the interobserver variability of this volumetric segmentation method was found to span an interquartile range (IQR) of 0.4ml, with a standard deviation of 0.5 ml and a bias of 0.1ml [Malan et al., 2012b].



Figure 3.2 – Cement flow was monitored using intra-operative fluoroscopy

Another study that applied this segmentation method to various periprosthetic tissues in clinical CT volumes reported a spatial volumetric interobserver agreement of between 90% and 95% (Median Dice Coefficient between 0.9 and 0.95) for segmentations performed by two subsequent human operators [Malan et al., 2012a].

Sub-volumes of injected cement that had leaked outside the desired target region, i.e. extra-osseously adjacent to the introduced cement injection needle in the femur, were separately labelled. Pre-operative fibrous tissue regions were determined as the union between residual periprosthetic radiolucent zones and the regions occupied by newly injected cement excluding regions of leaked cement.




Figure 3.3 – Cement flow was monitored using intra-operative fluoroscopy

Using these segmented regions we computed the following values for each patient:

- Lesion volume: Volume of pre-operative radiolucent fibrous tissue lesions (ml)
- Filling fraction: the percentage of pre-operative lesions that was filled by injected cement (%)
- Leakage fraction: the percentage of the total volume of injected cement that leaked into undesired areas (%)



Figure 3.4 – Lateral view X-ray of a patient’s hip after cement injection. Of all examined cases, this patient had the highest cement leakage percentage at 73% leakage of the injected 11.95 ml. This patient was part of the GDEPT group.

Segmented volumes were measured in millilitres and each volume distribution characterized by its median, range and IQR. Outliers were defined as being more than 1.5 IQRs outside the interval spanned by the first and third quartiles. Results were analysed using IBM SPSS Statistics 20 for Microsoft Windows (IBM Corporation, Armonk, NY, USA).

In comparing the observed differences between two sampled case series we used the nonparametric Mann Whitney U-test for independent groups, as our patients groups were small and we did not assume normal distribution of our measured parameters. A p value of 0.05 was taken to be statistically significant.




Figure 3.5 – A single axial slice through the CT volume of the same patient as in Fig. 3.4. In (a) the original image is shown. In (b) the regions of interest are labelled: Remainder of interface tissue zone (gray), injected cement at desired location (white), and leaked cement (hatched)

3.3 Results

The cement-only group's radiolucent lesion volumes ranged from 13.8 ml to 36.2 ml (median 27.8 ml, IQR 18.8 ml). The GDEPT group had lesion volumes ranging from 8.5 ml to 52.0 ml (median 20.9 ml, IQR 25 ml). These two distributions (Fig. 3.6) were statistically indistinguishable as measured by the Mann Whitney U-test ($p = 0.96$).

The injected cement volumes for the cement-only group ranged from 3.4 ml to 13.0 ml (median 5.2 ml, IQR 4.1 ml). For the GDEPT group, the injected cement volumes ranged from 6.9 ml to 27.8 ml (median 12.0 ml, IQR 14.3 ml). The observed difference in median injected cement volume was 6.8ml, which is more than one order of magnitude larger than the interobserver variability in the volume measurement technique as reported by [Malan et al., 2012b]. This difference in distributions was statistically significant ($p=0.007$), and is shown in Fig. 3.7.




Figure 3.6 – Volumes of osteolytic fibrous tissue for patients in the cement-only and GDEPT groups

The cement filling percentages achieved for the cement-only group ranged from 10.2% to 58.3% (median 20.7%, IQR 16.5%). The GDEPT group’s larger injected cement volumes also translated to higher cement filling fractions compared to the cement-only group. For the GDEPT group the cement filling percentages ranged from 16.5% to 52.1% (median 33.6%, IQR 31.8%).

There was a single outlier in the cement-only group representing an exceptionally high filling percentage (58.3%) which occurred for the femur with the smallest osteolytic lesion (13.8 ml) in this group (Fig. 3.8). Omitting this outlier resulted in a statistically significant difference in filling percentages between the cement-only and GDEPT-only groups ($p = 0.05$).

Without omission of the outlier in the cement-only group, the differences in cement filling fractions between the two groups did not reach statistical significance ($p=0.16$).




Figure 3.7 – Volumes of injected cement for patients in the cement-only and GDEPT groups

For the cement-only group the percentage of the injected cement that leaked out of the intended target (i.e. extra osseously) ranged between 0% and 40.1% (median 5.3%, IQR 35.6%). In comparison, the extra-femoral cement leakage in the GDEPT group ranged from 0.2% to 73.1% (median 39.6%, IQR 64.8%), and is shown in Fig. 3.9. Omitting the measurement corresponding to the outlier of Fig. 3.8, this difference was statistically significant ($p=0.05$). With the outlier included, the difference between these distributions did not reach statistical significance ($p = 0.06$).




Figure 3.8 – Cement filling percentages of the osteolytic lesions for patients in the cement-only and GDEPT groups




Figure 3.9 – Cement leakage percentages for patients in the cement-only and GDEPT groups

3.4 Discussion

Refixation of aseptic loosened hip stems by percutaneous cement injection can improve clinical outcomes for patients with loosened hip prostheses [de Poorter et al., 2008b]. Cement injection may be performed either with or without prior interface tissue treatment [Raaijmakers and Mulier, 2010, de Poorter, 2010]. The literature on this topic is limited. Earlier phase I-II preclinical and clinical trials found that the adenoviral vector CTL102 and the prodrug CB1954 were viable for removing interface tissue despite possible transient adverse side effects including fever, nausea and leukopenia [de Poorter et al., 2008b]. This study examines whether differences in cement-injection outcomes between these two approaches were observed.

Our results indicate that pre-operative treatment of interface tissue enabled more cement to be injected into the periprosthetic osteolytic lesions. This difference was statistically significant, even in our small sample population. The larger injected cement volumes for the patients who underwent pre-operative interface tissue removal was not correlated with the patients' pre-operative lesion volume, as the distribution of the latter was the same for the cement-only and GDEPT groups. With the exception of a single outlier, the larger injected cement volumes in the GDEPT group also manifested in higher fractions of cement filling of the target lesions. This greater degree of cement filling might translate to better refixation of loosened prostheses [Andreykiv et al., 2012]. The disadvantage to the hypothesised improved refixation in the GDEPT group may be side-effects caused by the treatment GDEPT itself, as well as adverse effects caused by bone cement leaking into e.g. surrounding muscle tissue. Given that elderly patients with aseptically loose hip prostheses present with invalidating pain and severely limited mobility, the benefits of better refixation are seen to outweigh the increased risk of transient side effects or cement leakage, which may cause temporary discomfort.

With the exception of a single outlier in the GDEPT group, the observed cement leakage percentages support the view that prior apoptosis-driven removal of fibrous interface tissue permits injected cement to flow more freely in the periprosthetic space during the cement injection procedure – both into and out of osteolytic target regions. An interesting question is whether use of more viscous cement is advisable where interface tissue has been sufficiently eliminated. We speculate that the association between lower cement viscosity and cement leakage in percutaneous vertebroplasty [Nieuwenhuijse et al., 2010] may also apply to the scenario of periprosthetic refixation by cement injection.

Osteolysis is a progressive process and is propagated by the presence of interface tissue [Agarwal, 2004]. Failure to completely remove pre-existing interface tissue may lead to progression or recurrence of osteolysis [Park et al., 2004]. A positive aspect of fibrous interface tissue removal that was not examined in this study is that fibrous tissue apoptosis and/or removal may reduce the self-propagating progression of osteolysis. Biomechanical finite element simulation has furthermore shown that interface tissue removal increases mechanical stability of the prosthesis [Andreykiv et al., 2012].

Limitations of this study include the small, consecutive, patient groups which arose from the experimental nature of the interventions described. A phase III study using the adenoviral vector CTL102 and prodrug CB1954, is currently awaiting funding at our institution. All bone cement used in this study was of comparable viscosity. The scope of our study excluded the research question of a possible relationship between cement leakage outside the femur and cement viscosity.

3.5 Conclusion

We conclude that the pre-operative GDEPT treatment of fibrous interface tissue had a measurable effect on the efficacy of percutaneous cement injection into the periprosthetic space. Only cement injection without fibrous tissue removal is currently possible in routine clinical practice due to a lack of available tissue removal agents and methodologies. We encourage continued research into minimally invasive methods for removing fibrous interface tissue prior to refixation by cement injection.

Acknowledgements

The authors wish to thank Anika Hoogenstraaten who helped us retrieve and organize historical clinical records at our hospital. We also acknowledge Dr Arian van Erkel, radiologist who assisted in the treatment of several of the patients described in this study. We also thank Samuel van de Velde who contributed his expertise to this paper. This research was supported by a grant from the Stichting Anna Fonds (Leiden, The Netherlands), as well as the Dutch Technology Foundation STW, which is the applied science division of the NWO and the Technology Programme of the Ministry of Economic Affairs (project number LKG 7943).